Group 1 - A class action lawsuit has been filed against Reckitt Benckiser Group Plc for alleged securities fraud and unlawful business practices [2][4] - Investors who purchased Reckitt securities during the Class Period have until August 4, 2025, to request appointment as Lead Plaintiff [2] - Reckitt's American Depositary Share (ADS) price experienced significant declines following jury verdicts related to its subsidiary Mead Johnson's negligence in warning about health risks associated with its products [4][5] Group 2 - On March 15, 2024, an Illinois jury awarded $60 million against Reckitt's Mead Johnson subsidiary for failing to warn about the risk of necrotizing enterocolitis (NEC) in preterm infants, leading to a nearly 14% drop in Reckitt's ADS price [4] - A subsequent lawsuit against Abbott Laboratories resulted in a $495 million award, similarly impacting Reckitt's ADS price with a nearly 9% decline [5] - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of fighting for victims of securities fraud [6]
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Reckitt Benckiser Group Plc of Class Action Lawsuit and Upcoming Deadlines - RBGLY